Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.
2.

Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines.

Ihmaid S, Al-Rawi J, Bradley C, Angove MJ, Robertson MN, Clark RL.

Bioorg Med Chem. 2011 Jul 1;19(13):3983-94. doi: 10.1016/j.bmc.2011.05.032. Epub 2011 May 24.

PMID:
21664823
3.

Synthesis, structural elucidation and DNA-dependant protein kinase and antiplatelet studies of 2-amino-[5, 6, 7, 8-mono and 7, 8-di-substituted]-1,3-benzoxazines.

Ihmaid S, Al-Rawi J, Bradley C.

Eur J Med Chem. 2010 Nov;45(11):4934-46. doi: 10.1016/j.ejmech.2010.07.066. Epub 2010 Aug 12.

PMID:
20800933
5.

Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation.

Saifuzzaman M, Morrison R, Zheng Z, Orive S, Hamilton J, Thompson PE, Al-Rawi JMA.

Bioorg Med Chem. 2017 Oct 15;25(20):5531-5536. doi: 10.1016/j.bmc.2017.08.022. Epub 2017 Aug 15.

PMID:
28838830
6.

Synthesis, identification and antiplatelet evaluation of 2-morpholino substituted benzoxazines.

Pritchard KM, Al-Rawi J, Bradley C.

Eur J Med Chem. 2007 Sep;42(9):1200-10. Epub 2007 Jan 27.

PMID:
17336427
7.

Synthesis of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as platelet aggregation inhibitors.

Tian X, Wang LY, Xia S, Li ZB, Liu XH, Yuan Y, Fang L, Zuo H.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):204-6. doi: 10.1016/j.bmcl.2011.11.027. Epub 2011 Nov 16.

PMID:
22137848
8.

Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8- and 6-aryl-substituted-1-3-benzoxazines.

Morrison R, Al-Rawi JM, Jennings IG, Thompson PE, Angove MJ.

Eur J Med Chem. 2016 Mar 3;110:326-39. doi: 10.1016/j.ejmech.2016.01.042. Epub 2016 Jan 27.

PMID:
26854431
9.

Synthesis of linear and angular aryl-morpholino-naphth-oxazines, their DNA-PK, PI3K, PDE3A and antiplatelet activity.

Morrison R, Zheng Z, Jennings IG, Thompson PE, Al-Rawi JMA.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5534-5538. doi: 10.1016/j.bmcl.2016.10.003. Epub 2016 Oct 5.

PMID:
27765510
10.

The synthesis of 4,7-disubstituted-2H-benzo[b][1,4]-oxazin-3(4H)-ones using Smiles rearrangement and their in vitro evaluation as platelet aggregation inhibitors.

Xia S, Liu JQ, Wang XH, Tian Y, Wang Y, Wang JH, Fang L, Zuo H.

Bioorg Med Chem Lett. 2014 Mar 15;24(6):1479-83. doi: 10.1016/j.bmcl.2014.02.014. Epub 2014 Feb 14.

PMID:
24565904
11.

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

Hollick JJ, Rigoreau LJ, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone MG, Menear KA, Martin NM, Matthews I, Newell DR, Ord R, Richardson CJ, Smith GC, Griffin RJ.

J Med Chem. 2007 Apr 19;50(8):1958-72. Epub 2007 Mar 20.

PMID:
17371003
12.

DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.

Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ.

J Med Chem. 2010 Dec 23;53(24):8498-507. doi: 10.1021/jm100608j. Epub 2010 Nov 16.

PMID:
21080722
13.

1,4-Benzoxazine-3(4H)-ones as potent inhibitors of platelet aggregation: design, synthesis and structure-activity relations.

Liu C, Tan JL, Xiao SY, Liao JF, Zou GR, Ai XX, Chen JB, Xiang Y, Yang Q, Zuo H.

Chem Pharm Bull (Tokyo). 2014;62(9):915-20. Epub 2014 Jul 9.

14.

DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

Clapham KM, Bardos J, Finlay MR, Golding BT, Griffen EJ, Griffin RJ, Hardcastle IR, Menear KA, Ting A, Turner P, Young GL, Cano C.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):966-70. doi: 10.1016/j.bmcl.2010.12.047. Epub 2010 Dec 13.

PMID:
21216595
15.

Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.

Anderluh M, Cesar J, Stefanic P, Kikelj D, Janes D, Murn J, Nadrah K, Tominc M, Addicks E, Giannis A, Stegnar M, Dolenc MS.

Eur J Med Chem. 2005 Jan;40(1):25-49.

PMID:
15642407
16.

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GC, Thommes P, Ting A, Griffin RJ.

J Med Chem. 2013 Aug 22;56(16):6386-401. doi: 10.1021/jm400915j. Epub 2013 Aug 1.

PMID:
23855836
17.

Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins.

Di Braccio M, Grossi G, Roma G, Grazia Signorello M, Leoncini G.

Eur J Med Chem. 2004 May;39(5):397-409.

PMID:
15110966
18.

N-substituted indole carbohydrazide derivatives: synthesis and evaluation of their antiplatelet aggregation activity.

Mirfazli SS, Kobarfard F, Firoozpour L, Asadipour A, Esfahanizadeh M, Tabib K, Shafiee A, Foroumadi A.

Daru. 2014 Sep 20;22:65. doi: 10.1186/s40199-014-0065-6.

19.

Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.

Ilić M, Kikelj D, Ilaš J.

Eur J Med Chem. 2012 Apr;50:255-63. doi: 10.1016/j.ejmech.2012.01.059. Epub 2012 Feb 8.

PMID:
22365562
20.

Design, synthesis and in vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides.

Liu XJ, Shi XX, Zhong YL, Liu N, Liu K.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6591-5. doi: 10.1016/j.bmcl.2012.09.001. Epub 2012 Sep 11.

PMID:
23010272

Supplemental Content

Support Center